세계의 경피 흡수형 나이아신아미드 시장 예측(-2032년) : 제품 형상별, 유통 채널별, 용도별, 지역별 분석

According to Stratistics MRC, the Global Transdermal Niacinamide Market is accounted for $70.87 million in 2025 and is expected to reach $113.06 million by 2032 growing at a CAGR of 6.9% during the forecast period. Transdermal niacinamide is a dermatological and cosmeceutical solution delivering vitamin B3 directly through the skin via advanced formulations such as patches, gels, or creams. This method enhances bioavailability, bypassing oral metabolism while addressing targeted concerns like acne, hyperpigmentation, and inflammation. Its adoption is fueled by rising preference for non-invasive therapies, evidence-based skincare, and the broader trend toward personalized dermatology, making it a promising segment in medical aesthetics and dermatological care.

According to Springer's Drug Delivery and Translational Research (2024), niacinamide is widely used in topical formulations due to its skin-brightening, anti-aging, and barrier-protective properties. Concentrations up to 20% are used in commercial products, and its efficacy is linked to its role in NAD+/NADH metabolism.

Market Dynamics:

Driver:

Growing prevalence of skin disorders

The growing prevalence of skin disorders continues to drive adoption of transdermal niacinamide formulations, as consumers seek effective solutions for conditions such as hyperpigmentation, acne, and atopic dermatitis. Increasing awareness of niacinamide's dermatological benefits, such as improved skin barrier function and enhanced hydration, further strengthens its demand across both therapeutic and cosmetic segments. Additionally, the rise in aging populations globally is fueling adoption due to rising dermatological concerns. Furthermore, recent innovations in skincare delivery systems integrate niacinamide more effectively, positively contributing to steady market expansion.

Restraint:

High cost of advanced transdermal delivery systems

The high cost associated with advanced delivery mechanisms, including microneedle patches, nanoparticle carriers, and encapsulation technologies, is hampering the growth. These innovations, while improving bioavailability, significantly increase product development and consumer pricing, limiting mass adoption. Additionally, manufacturers face higher R&D expenditures and compliance costs in regulated markets, further impacting affordability. Furthermore, lesser-developed economies often struggle with cost competitiveness compared to traditional oral or topical alternatives. This price sensitivity may restrict uptake, thereby slowing broader market penetration.

Opportunity:

Development of novel delivery mechanisms

The development of novel delivery mechanisms integrates nanotechnology, microneedles, and hydrogel systems for improved skin penetration. Advanced encapsulation technologies provide controlled release, ensuring higher stability and efficacy, thereby attracting pharmaceutical and cosmeceutical collaborations. Additionally, multi-functional products catering to both therapeutic and cosmetic needs are stimulating innovation pipelines. With rising consumer preference for personalized skincare, these advancements open avenues for wider product differentiation, accelerating adoption and positioning niacinamide as a versatile transdermal ingredient.

Threat:

Potential skin irritation and allergic reactions

Prolonged use at higher concentrations may trigger redness, contact dermatitis, or barrier disruption in individuals with sensitive skin, thereby limiting compliance. Regulatory bodies emphasize stringent dermatological testing, increasing time-to-market for new formulations. Furthermore, negative consumer reviews regarding irritation can harm product reputation, particularly across cosmetic channels. This risk necessitates greater investment in hypoallergenic formulations and dermatological trials, as safety perceptions will continue to influence patient and consumer acceptance significantly.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the transdermal niacinamide market. On one hand, disruptions in raw material supply chains and manufacturing led to short-term challenges, particularly in distribution across emerging economies. However, rising consumer demand for skincare products due to "maskne" and emphasis on home-based dermatological care boosted usage. Additionally, e-commerce growth accelerated over-the-counter adoption of niacinamide-based transdermal solutions. Furthermore, clinical research on skin health and immunity strengthened niacinamide's profile as a desirable active ingredient.

The gels & creams segment is expected to be the largest during the forecast period

The gels & creams segment is expected to account for the largest market share during the forecast period, driven by their ease of application, consumer familiarity, and widespread distribution through retail, pharmacy, and online channels. Additionally, this segment benefits from versatility in formulations, addressing multiple skin disorders, including acne, dark spots, and barrier dysfunction. The increasing preference for cosmeceutical products with anti-aging and skin-brightening functions also supports market expansion.

The dermatology clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the dermatology clinics segment is predicted to witness the highest growth rate, supported by growing demand for advanced and personalized skincare treatments. Clinics serve as trusted channels for delivering dermatologist-recommended formulations, especially for patients dealing with chronic skin disorders or requiring professional-grade interventions. Furthermore, enhanced clinical research validating niacinamide's efficacy and safety reinforces adoption through these professional outlets. With increasing patient awareness and the rising emphasis on evidence-based therapies, dermatology clinics are expected to remain the fastest-expanding distribution route.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, primarily due to the high prevalence of skin disorders, growing consumer preference for premium skincare products, and early adoption of advanced delivery technologies. Well-established pharmaceutical and cosmetic industries in the U.S. and Canada are driving product innovations and clinical research. Furthermore, strong healthcare infrastructure supports dermatological treatments, and patent-driven R&D enhances market competitiveness. Increasing consumer demand for skin-brightening and anti-aging solutions will continue to strengthen North America's dominant regional position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rising consumer awareness of skincare, rapid urbanization, and growing disposable incomes. Countries such as China, Japan, and South Korea are leading in skincare innovation, integrating niacinamide across both therapeutic and cosmetic categories. Additionally, expanding e-commerce platforms and K-beauty trends are accelerating adoption across younger demographics. The increased investments by multinational cosmetic firms in Asia-Pacific manufacturing facilities strengthen supply chains. With evolving consumer behavior and preference for advanced formulations, the region is set to deliver the fastest growth trajectory globally.

Key players in the market

Some of the key players in Transdermal Niacinamide Market include DSM-Firmenich, BASF, Merck KGaA, Lonza, Bactolac Pharmaceutical, Evonik Industries, Givaudan, Procter & Gamble, Unilever, L'Oreal, Estee Lauder, Beiersdorf, Johnson & Johnson, Amway, Shiseido, Coty, Paula's Choice, The Ordinary (Deciem), Galderma, and Rohto Pharmaceutical.

Key Developments:

In October 2024, BASF's Personal Care business is launching a new synthetic peptide for skin care applications. Inspired by the natural regenerative process of the skin, Pepsensyal(TM) (INCI: Mannitol (and) Acetyl sh-Tetrapeptide-1 (and) Lauroyl sh-Tetrapeptide-1) has been clinically proven to reduce and delay the first visible signs of aging. The new ingredient is a response to the slow-aging trend, which reflects a shift in consumer attitudes: Rather than fighting the natural aging process, consumers are increasingly concerned with healthy aging through a holistic, preventative approach to skin care.

In October 2024, DSM-Firmenich has developed an upgraded version of their Niacinamide PC product to mark its 10th anniversary. The enhanced formula provides all the traditional benefits with improved efficacy for menopausal skin concerns, addressing dryness, sensitivity, fine lines, and wrinkles by strengthening the skin barrier. Their research shows 27% reduction in transepidermal water loss when 2% niacinamide was applied twice daily for 4 weeks.

In September 2024, Evonik has launched two new products to meet the demands for sustainable, natural actives in the beauty and personal care markets. The two newly launched products are CapilAcid(TM), an active ingredient derived from the Maqui fruit which is a comprehensive protector and powerful antioxidant for the hair, and Oleobiota(TM), an active ingredient sourced sustainably from the Misiones rainforest for sebum-normalizing skin care. Both products originate from the company Novachem, which was acquired by Evonik one year ago and is being integrated into the company's Care Solutions business.

Product Forms Covered:

• Gels & Creams
• Serums
• Patches
• Microneedle Patches

Distribution Channels:

• Hospital Pharmacies
• Retail & Convenience Stores
• Online Retail/E-commerce
• Dermatology Clinics

Applications Covered:

• Medical Dermatology
• Cosmetic Dermatology

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Transdermal Niacinamide Market, By Product Form

• 5.1 Introduction
• 5.2 Gels & Creams
• 5.3 Serums
• 5.4 Patches
• 5.5 Microneedle Patches

6 Global Transdermal Niacinamide Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Hospital Pharmacies
• 6.3 Retail & Convenience Stores
• 6.4 Online Retail/E-commerce
• 6.5 Dermatology Clinics

7 Global Transdermal Niacinamide Market, By Application

• 7.1 Introduction
• 7.2 Medical Dermatology
  • 7.2.1 Acne
  • 7.2.2 Rosacea & Inflammation
  • 7.2.3 Psoriasis & Other Skin Conditions
• 7.3 Cosmetic Dermatology
  • 7.3.1 Anti-aging
  • 7.3.2 Skin Brightening & Pigmentation
  • 7.3.3 Skin Barrier Repair

8 Global Transdermal Niacinamide Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 DSM-Firmenich
• 10.2 BASF
• 10.3 Merck KGaA
• 10.4 Lonza
• 10.5 Bactolac Pharmaceutical
• 10.6 Evonik Industries
• 10.7 Givaudan
• 10.8 Procter & Gamble
• 10.9 Unilever
• 10.10 L'Oreal
• 10.11 Estee Lauder
• 10.12 Beiersdorf
• 10.13 Johnson & Johnson
• 10.14 Amway
• 10.15 Shiseido
• 10.16 Coty
• 10.17 Paula's Choice
• 10.18 The Ordinary (Deciem)
• 10.19 Galderma
• 10.20 Rohto Pharmaceutical